Abbott Laboratories (Pakistan) Limited
Public listed healthcare and pharmaceutical company · Karachi · Pakistan
Public listed healthcare company in Pakistan engaged in pharmaceuticals, nutrition, diagnostics, diabetes care and consumer healthcare.
What is sourced, and how recent is it?
Regulatory-source portfolio data and company-supplied/corporate profile fields are tracked separately. Company claim/verification status is separate from source quality. An unclaimed company can still have a fully official-source-observed portfolio.
Company profile
- Company type
- Public listed healthcare and pharmaceutical company
- Address
- Opposite Radio Pakistan Transmission Centre, Hyderabad Road, Landhi, Karachi, Pakistan
- Website
- pk.abbott ↗
- Phone
- +92 21 111 222 688
- Official contact
- Contact page ↗
- Corporate source details checked
- 16 Aug 2026
- Corporate profile completeness
- 88%
Company location
A sourced company location is recorded. Use the map link below for directions.
Portfolio at a glance
RegistrationA unique regulatory registration number. One registration may have more than one strength/form/pack presentation.
PresentationA distinct medicine presentation, such as a particular strength, dosage form and pack.
IndexedA canonical MedInfoBase presentation that passed MedInfoBase identity and publication controls.
Source observedAn additional presentation observed in an official DRAP source but not counted as an indexed MedInfoBase presentation.
Registry onlyAn exact registry-verified registration not otherwise represented by an indexed or source-observed presentation.
Registry verifiedAn exact registration match found in an official DRAP registry source. This is evidence status, not a commercial ranking.
How complete is this profile?
Downloadable company intelligence charts
Copy or download any chart as a presentation-ready PNG. Every exported chart keeps MedInfoBase attribution and the source company-profile URL.
Therapeutic Portfolio Mix
Shows where the company portfolio is concentrated across broad therapeutic areas.
Portfolio distribution, not sales or market-share data.
Dosage Form Portfolio
Shows how the company portfolio is distributed across tablets, capsules, injections, liquids and other forms.
Counts are product presentations, not production or sales volumes.
Equivalent Price Position
Shows whether safely comparable products are below, near or above the peer median unit price.
This is price-position intelligence, not sales, demand or market-share data.
Closest Portfolio Competitors
Highlights other manufacturers with the greatest generic overlap with this company portfolio.
Competitor ranking is based on shared generics in MedInfoBase, not commercial sales performance.
Therapeutic areas
High-level clinical areas represented by this company’s current MedInfoBase portfolio.
Drug classes
More specific classes derived from the canonical generic and preserved curated classifications.
Dosage forms
How MedInfoBase classifies the portfolio
MedInfoBase uses a two-level taxonomy. Therapeutic area is a broad portfolio category, while drug class is the more specific pharmacological or clinical class. Existing curated classifications are preserved. Blank records are assigned conservatively from the canonical generic name and, when available, ATC information. Multi-use medicines may be placed in a cross-therapeutic category rather than forced into a single indication.
Deepest brand families
Unit-price positioning vs equivalent products
How MedInfoBase calculates price position
Only current prices with safely interpretable pack quantities are used. A product is compared only with the same generic, same stated strength, same dosage form and a compatible unit basis such as tablet, capsule, mL or gram. These are database-derived price comparisons, not sales or market-share estimates.
Portfolio overlap
Companies sharing the largest number of generics with this portfolio. This measures product overlap, not commercial performance.
Observed database signals
These dates describe records observed by MedInfoBase. They should not be interpreted as product launch dates or sales activity.
Medicine portfolio
This unified portfolio keeps three evidence lanes distinct: indexed MedInfoBase presentations, additional source-observed presentations, and registry-only registrations that are not otherwise represented. A registration number is not the same thing as a presentation, and source-observed rows are not counted as indexed. Source-only rows with a strength/form/pack contradiction remain visible as evidence but the conflicting field is held for normalization.
| Brand | Generic | Strength | Form | Pack | Registration | Source-listed price | Unit price | Price position |
|---|---|---|---|---|---|---|---|---|
| ABOCAIN SPINAL | Bupivacaine | 7.5 mg/mL | Injection | 5x2ml | 018143 | PKR 510.83 | PKR 51.08/mL | 65% above median |
| ACYCLOVIR | Aciclovir | 500 mg | Injection | 1x10ml | 021397 | PKR 1,912.41 | PKR 191.24/mL | No comparator |
| ACYCLOVIR | Aciclovir | 1 G | Injection | 1s | 021398 | PKR 2,175.51 | PKR 2,175.51/vial/unit | No comparator |
| ATRELAX | Atracurium besylate | 10 mg/mL | Injection | 5x5ml | 011031 | PKR 2,231.75 | PKR 89.27/mL | 53% above median |
| ATRELAX | Atracurium besylate | 10 mg/mL | Injection | 5x2.5ml | 018010 | PKR 1,154.02 | PKR 92.32/mL | 58% above median |
| BRUFEN | Ibuprofen | 200 mg | Tablet | 50X10S (For Export Purpose only) | 000072 | PKR 1,333.25 | — | No comparator |
| BRUFEN | Ibuprofen | 200 mg | Tablet | 10X10S | 000072 | PKR 459.48 | PKR 4.59/tablet | 103% above median |
| BRUFEN | Ibuprofen | 400 mg | Tablet | 25X10S | 001541 | PKR 1,052.13 | PKR 4.21/tablet | 20% above median |
| BRUFEN | Ibuprofen | 400 MG | Tablet | 10 X 10s | 001541 | PKR 420.84 | PKR 4.21/tablet | 20% above median |
| BRUFEN | Ibuprofen | 100 mg/5 mL | Suspension | 90ML | 004595 | PKR 81.37 | PKR 0.90/mL | Near median |
| BRUFEN | Ibuprofen | 100 mg/5 mL | Syrup | 120ML | 004595 | PKR 135.50 | PKR 1.13/mL | 26% above median |
| BRUFEN | Ibuprofen | 600 mg | Tablet | 3X12's | 007850 | PKR 255.16 | PKR 7.09/tablet | 14% above median |
| BRUFEN | Ibuprofen | 800 mg | Tablet | 2 X 12's | 018388 | PKR 254.14 | PKR 10.59/tablet | No comparator |
| BRUFEN | Ibuprofen | 200 mg/5 mL | Suspension | 90ML | 070851 | PKR 123.91 | PKR 1.38/mL | 11% above median |
| BRUFEN | Ibuprofen | 200 mg/5 mL | Syrup | 120ML | 070851 | PKR 135.06 | PKR 1.13/mL | No comparator |
| BRUFEN | Ibuprofen | 200 mg/5 mL | Suspension | 60ML | 070851 | PKR 71.83 | PKR 1.20/mL | 6% below median |
| BRUFEN | Ibuprofen | 400 mg/4 mL | IV injection | 4mlx10's | 093088 | PKR 1,863.80 | PKR 46.60/mL | Near median |
| BRUFEN | Ibuprofen | 400 mg/4 mL | IV injection | 4mlx1's | 093088 | PKR 194.15 | PKR 48.54/mL | Near median |
| CECON-500 | Ascorbic acid | 500 mg | Chewable tablet | 40s | 006119 | PKR 208.60 | PKR 5.22/tablet | 293% above median |
| DUPHALAC | Lactulose | 66.7 g/100 mL | Syrup | 240ML | 006655 | PKR 626.55 | PKR 2.61/mL | Near median |
| Duphalac | Lactulose | 66.7 g/100 mL | Syrup | 120ML | 006655 | PKR 331.83 | PKR 2.77/mL | 9% above median |
| EPIVAL | Divalproex sodium | 250 mg | Tablet | 10X10's | 007160 | PKR 967.17 | PKR 9.67/tablet | 30% above median |
| EPIVAL | Divalproex sodium | 500 mg | Tablet | 10X10's | 007161 | PKR 2,420.46 | PKR 24.20/tablet | 108% above median |
| EPIVAL | Sodium valproate | 250 mg/5 mL | Syrup | 60ml | 012079 | PKR 134.81 | PKR 2.25/mL | 24% above median |
| EPIVAL | Sodium valproate | 250 mg/5 mL | Syrup | 120ml | 012079 | PKR 339.33 | PKR 2.83/mL | 56% above median |
| EPIVAL | Sodium valproate | 250 mg/5 mL | Syrup | 240ml | 012079 | PKR 529.50 | PKR 2.21/mL | 22% above median |
| EPIVAL | Valproic acid | 500 mg | Tablet | 5X10's | 022481 | PKR 1,540.29 | PKR 30.81/tablet | 231% above median |
| Epival I.V. | Sodium valproate | 500 mg/5 mL | IV injection | 1 X 5ML | 023349 | PKR 257.71 | PKR 51.54/mL | No comparator |
| Influvac | Influenza vaccine, inactivated | 15 mcg haemagglutinin/strain per 0.5 mL | Suspension for injection | 0.5ml X 10's | 028437 | PKR 9,241.37 | PKR 1,848.27/mL | No comparator |
| Influvac | Influenza vaccine (inactivated surface antigen) | 15 mcg HA per recommended strain / 0.5 mL | Prefilled syringe vaccine injection | 1's | 028437 | PKR 906.93 | PKR 906.93/syringe | No comparator |
| Influvac Tetra | Influenza vaccine (inactivated surface antigen, quadrivalent) | 15 mcg HA per each of 4 strains / 0.5 mL | Prefilled syringe vaccine injection | 1's | 107910 | PKR 2,984.85 | PKR 2,984.85/syringe | No comparator |
| Influvac Tetra | Influenza vaccine (inactivated surface antigen, quadrivalent) | 15 mcg | Prefilled syringe injection | 10's | 107910 | PKR 28,653.96 | PKR 2,865.40/syringe | No comparator |
| KLARICID | Clarithromycin | 250 MG | Tablet | 10's | 013149 | PKR 740.65 | PKR 74.07/tablet | 56% above median |
| KLARICID | Clarithromycin | 125 mg/5 mL | Granules for oral suspension | 30ML | 015104 | PKR 325.47 | PKR 10.85/mL | No comparator |
| KLARICID | Clarithromycin | 500 mg | Tablet | 2 X 7's | 018145 | PKR 1,875.26 | PKR 133.95/tablet | 60% above median |
| KLARICID | Clarithromycin | 500 mg | Tablet | 10's | 018145 | PKR 1,339.39 | PKR 133.94/tablet | 60% above median |
| KLARICID | Clarithromycin | 500 mg | Prolonged-release tablet | 5's | 020203 | PKR 668.55 | PKR 133.71/tablet | 51% above median |
| KLARICID | Clarithromycin | 500 mg | Prolonged-release tablet | 2 X 7's | 020203 | PKR 1,722.43 | PKR 123.03/tablet | 39% above median |
| KLARICIDSource observed | Clarithromycin | 250 mg/5 mL | Held for normalizationSource reported: Tablet · structural field conflict | 60ML | 076148Official source ↗ | No indexed price | — | — |
| Klaricid I.V. | Clarithromycin | 500 mg | IV infusion | 1 X 0.5 GM VIAL | 018142 | PKR 520.77 | — | No comparator |
| KREON | Pancreatin | 150 mg | Capsule | 20s | 047677 | PKR 559.42 | PKR 27.97/capsule | 6% above median |
| KREON | Pancreatin | 150 mg | Capsule | 200s | 047677 | PKR 5,146.36 | PKR 25.73/capsule | 7% below median |
| KREON 10000 | Pancreatin | 150 mg | Capsule | 50s | 047677 | PKR 1,356.16 | PKR 27.12/capsule | Near median |
| KREON 10000 | Pancreatin | 150 mg | Enteric-coated tablet | 100s | 047677 | PKR 1,666.95 | PKR 16.67/tablet | No comparator |
| Levelanz | Levetiracetam | 100 mg/mL | Oral solution | 120ml | 108822 | PKR 1,100.67 | PKR 9.17/mL | 32% below median |
| LEVELANZ ORAL | Levetiracetam | 100 mg/mL | Oral solution | 60ml | 108822 | PKR 550.34 | PKR 9.17/mL | 32% below median |
| LEVELANZ ORAL | Levetiracetam | 100 mg/mL | Oral solution | 30ml | 108822 | PKR 290.46 | PKR 9.68/mL | 29% below median |
| LUMAT | Artemether + Lumefantrine | 20 mg + 120 mg | Tablet | 16's | 083045 | PKR 566.58 | PKR 35.41/tablet | 11% below median |
| LUMAT DS 40/240 | Artemether | 40 mg | Tablet | 10's | 084712 | PKR 548.87 | PKR 54.89/tablet | 15% below median |
| MOKSI | Moxifloxacin | 400 mg | Tablet | 5's | 067550 | PKR 994.57 | PKR 198.91/tablet | 8% above median |
MedInfoBase company-intelligence methodology
This page is generated from MedInfoBase medicine, generic, company, price and official-source records. Unverified third-party discovery records are retained internally for coverage auditing and are not published as company registrations. Portfolio leaders are ranked by presentation depth, not sales. Price-position metrics are calculated from current official-source prices normalized to compatible units and compared only against like-for-like products with the same generic, stated strength and dosage form.
Not currently included: sales volume, revenue by brand, market share, prescription volume or best-selling rankings. MedInfoBase will display those only when supported by a defensible licensed, public or company-verified source.
Cite this record
Manufacturer recordRecords change over time. Please cite the access date so readers can locate the version you used.